Atlas Trials

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

Clinical trial NCT03617523 · COMPLETED

Trial details

NCT number
NCT03617523
Sponsor
Sanofi Pasteur, a Sanofi Company
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Influenza
Start date
2018-09-10
Primary completion
2018-11-12
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.